Login Register Cart 0
Generic placeholder image

Clinical Cancer Drugs

Editor-in-Chief

ISSN (Print): 2212-697X
ISSN (Online): 2212-6988

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

A Maximum Entropy Estimator for the Average Survival Time Differences between Two Groups

Author(s): Marian Manciu*, Sorour Hosseini and Joscelyne Guzman-Gonzalez

Volume 7, Issue 2, 2020

Page: [107 - 112] Pages: 6

DOI: 10.2174/2212697X07999200331120654

Price: $65

Abstract

Background: Statistical methods commonly used in survival analysis typically provide the probability that the difference between groups is due to chance, but do not offer a reliable estimate of the average survival time difference between groups (the difference between median survival time is usually reported).

Objective: We suggest a Maximum-Entropy estimator for the average Survival Time Difference (MESTD) between groups.

Methods: The estimator is based on the extra survival time, which should be added to each member of the group, to produce the maximum entropy of the result (resulting in the groups becoming most similar). The estimator is calculated only from time to event data, does not necessarily assume hazard proportionality and provides the magnitude of the clinical differences between the groups.

Results: Monte Carlo simulations show that, even at low sample numbers (much lower than the ones needed to prove that the two groups are statistically different), the MESTD estimator is a reliable predictor of the clinical differences between the groups, and therefore can be used to estimate from (low sample numbers) preliminary data whether or not the large sample number experiment is worth pursuing.

Conclusion: By providing a reasonable estimate for the efficacy of a treatment (e.g., for cancer) even for low sample data, it might provide useful insight in testing new methods for treatment (for example, for quick testing of multiple combinations of cancer drugs).

Keywords: Survival analysis, entropy, non-parametric inference, cancer drugs MESTD, combinations of cancer drugs, efficacy.

Graphical Abstract

[1]
Allison PD. Survival analysis using SAS: A practical guide. SAS Institute 2010.
[2]
Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc [Ser A] 1972; 135(2): 185-207.
[http://dx.doi.org/10.2307/2344317]
[3]
Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52(1-2): 203-23.
[http://dx.doi.org/10.1093/biomet/52.1-2.203 ] [PMID: 14341275]
[4]
Breslow N. Covariance analysis of censored survival data. Biometrics 1974; 30(1): 89-99.
[http://dx.doi.org/10.2307/2529620 ] [PMID: 4813387]
[5]
Tarone RE, Ware J. On distribution-free tests for equality of survival distributions. Biometrika 1977; 64(1): 156-60.
[http://dx.doi.org/10.1093/biomet/64.1.156]
[6]
Cox DR. Partial likelihood. Biometrika 1975; 62(2): 269-76.
[http://dx.doi.org/10.1093/biomet/62.2.269]
[7]
Zaman Q, Pfeiffer KP. Does Log-rank test give satisfactory results? J Appl Quant Methods 2012; 7(1): 3-8.
[8]
Berty HP, Shi H, Lyons-Weiler J. Determining the statistical significance of survivorship prediction models. J Eval Clin Pract 2010; 16(1): 155-65.
[http://dx.doi.org/10.1111/j.1365-2753.2009.01199.x ] [PMID: 20367827]
[9]
Shannon CE. A mathematical theory of communication. Bell Syst Tech J 1948; 27(3): 379-423.
[http://dx.doi.org/10.1002/j.1538-7305.1948.tb01338.x]
[10]
De Martino A, De Martino D. An introduction to the maximum entropy approach and its application to inference problems in biology. Heliyon 2018; 4(4): e004596.
[http://dx.doi.org/10.1016/j.heliyon.2018.e00596 ] [PMID: 29862358]
[11]
Motulsky H. Intuitive biostatistics: A nonmathematical guide to statistical thinking. USA: Oxford University Press 2013.
[12]
Wilcoxon F. Individual comparisons by ranking methods. Biom Bull 1945; 1(6): 80-3.
[http://dx.doi.org/10.2307/3001968]
[13]
Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947; 18(1): 50-60.
[http://dx.doi.org/10.1214/aoms/1177730491]
[14]
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2014, Vienna, Austria. http://www.R-project.org/
[15]
Loprinzi CL, Laurie JA, Wieand HS, et al. North Central Cancer Treatment Group. Prospective evaluation of prognostic variables from patient-completed questionnaires. J Clin Oncol 1994; 12(3): 601-7.
[http://dx.doi.org/10.1200/JCO.1994.12.3.601 ] [PMID: 8120560]
[16]
George SL, Desu MM. Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis 1974; 27(1): 15-24.
[http://dx.doi.org/10.1016/0021-9681(74)90004-6 ] [PMID: 4592596]

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy